Insilico Medicine

52 employees

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.

Basic info

Industry

biotechnology

Sectors

Biotechnology

Artificial Intelligence

biomarker development

Pharmaceutical

GANs-RL

aging research

artificial intelligence

reinforcement learning

deep learning

Health Care

drug discovery

longevity

Generative adversarial networks

GANs

Date founded

2014

Funding rounds raised

Total raised

$255M

from 33 investors over 33 rounds

Insilico Medicine raised $35M on August 10, 2022

Investors: Prosperity7 Ventures, Wilson Sonsini Goodrich & Rosati, BHR Partners, Warburg Pincus LLC, B Capital Group, Qiming Venture Partners and BOLD Capital Partners

Insilico Medicine raised $60M on June 6, 2022

Investors: Qiming Venture Partners, B Capital Group, BHR Partners, Warburg Pincus LLC and BOLD Capital Partners

Insilico Medicine raised undisclosed on January 11, 2022

Investors: Fosun Pharma

Insilico Medicine raised $255M on June 22, 2021

Investors: President International Development Corp., OrbiMed Advisors, Maison Capital, Sage Partners, Warburg Pincus LLC, Qiming Venture Partners and Sequoia Capital China

Insilico Medicine raised $37M on September 9, 2019

Investors: Formic Ventures, Lilly Asia Ventures, BOLD Capital Partners, F-Prime Capital Partners, Qiming Venture Partners, Longevity Vision Fund and Harmonix

Insilico Medicine raised $6M on June 18, 2018

Investors: WuXi AppTec, BOLD Capital Partners and Juvenescence

Insilico Medicine raised $2.8M on February 27, 2017

Investors: A-Level Capital

Insilico Medicine raised $1.2M on November 16, 2014

Investors: Deep Knowledge Group

Insilico Medicine raised $300K on April 16, 2014